Wet (Neovascular) Age-Related Macular Degeneration
Description: Clinical trial evaluating whether the use of a higher dose of aflibercept, which is already FDA-approved for treatment of wet age-related macular degeneration (AMD), will allow for less frequent eye injections in wet AMD.
Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
Sponsor: Bayer Pharmaceuticals
Principal Investigator: Scott McClintic, MD
Study Coordinator: Marina Sprauer, LPN
Status: Actively Enrolling